OPDIVO QVANTIG Trademark

Trademark Overview

On Friday, May 5, 2023, a trademark application was filed for OPDIVO QVANTIG with the United States Patent and Trademark Office. The USPTO has given the OPDIVO QVANTIG trademark a serial number of 97922321. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Saturday, November 29, 2025. This trademark is owned by Bristol-Myers Squibb Company. The OPDIVO QVANTIG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of cancer.
opdivo qvantig

General Information

Serial Number97922321
Word MarkOPDIVO QVANTIG
Filing DateFriday, May 5, 2023
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateSaturday, November 29, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 10, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of cancer.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 11, 2023
Primary Code005
First Use Anywhere DateFriday, February 28, 2025
First Use In Commerce DateFriday, February 28, 2025

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events

Event DateEvent Description
Tuesday, May 9, 2023NEW APPLICATION ENTERED
Thursday, May 11, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 1, 2023ASSIGNED TO EXAMINER
Thursday, June 1, 2023NON-FINAL ACTION WRITTEN
Thursday, June 1, 2023NON-FINAL ACTION E-MAILED
Thursday, June 1, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 23, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 23, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 23, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 31, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 20, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 10, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 10, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 5, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 20, 2024SOU TEAS EXTENSION RECEIVED
Monday, May 20, 2024SOU EXTENSION 1 FILED
Monday, May 20, 2024SOU EXTENSION 1 GRANTED
Tuesday, May 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 25, 2024SOU TEAS EXTENSION RECEIVED
Monday, November 25, 2024SOU EXTENSION 2 FILED
Monday, November 25, 2024SOU EXTENSION 2 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 5, 2025SOU TEAS EXTENSION RECEIVED
Thursday, June 5, 2025SOU EXTENSION 3 FILED
Thursday, June 5, 2025SOU EXTENSION 3 GRANTED
Friday, June 6, 2025TEAS STATEMENT OF USE RECEIVED
Monday, September 15, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, November 29, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, June 6, 2025USE AMENDMENT FILED
Saturday, November 29, 2025STATEMENT OF USE PROCESSING COMPLETE

Related Keywords

qvantig opdivo prevention cancer treatment human preparations pharmaceutical